Amplify Weight Loss Drug & Treatment ETF (THNR)

NYSEARCA: THNR · Real-Time Price · USD
22.88
0.00 (0.00%)
Jul 8, 2025, 4:00 PM - Market open
0.00%
Assets $2.98M
Expense Ratio 0.59%
PE Ratio 19.28
Shares Out 130,000
Dividend (ttm) $0.22
Dividend Yield 0.96%
Ex-Dividend Date Dec 30, 2024
Payout Frequency n/a
Payout Ratio 18.45%
Volume n/a
Open 22.88
Previous Close 22.88
Day's Range 22.88 - 22.88
52-Week Low 18.56
52-Week High 28.19
Beta n/a
Holdings 22
Inception Date May 21, 2024

About THNR

Fund Home Page

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.

Asset Class Equity
Category Health
Region Global
Stock Exchange NYSEARCA
Ticker Symbol THNR
Index Tracked VettaFi Weight Loss Drug & Treatment Index

Top 10 Holdings

69.47% of assets
Name Symbol Weight
Eli Lilly and Company LLY 12.41%
Novo Nordisk A/S NVO 11.01%
Regeneron Pharmaceuticals, Inc. REGN 7.21%
Amgen Inc. AMGN 6.90%
Chugai Pharmaceutical Co., Ltd. 4519 6.34%
Pfizer Inc. PFE 5.27%
Gilead Sciences, Inc. GILD 5.15%
Merck & Co., Inc. MRK 5.10%
AbbVie Inc. ABBV 5.08%
Roche Holding AG ROG 4.98%
View More Holdings

Dividends

Ex-Dividend Amount Pay Date
Dec 30, 2024 $0.2199 Dec 31, 2024
Full Dividend History

Performance

THNR had a total return of -12.05% in the past year, including dividends. Since the fund's inception, the average annual return has been -8.12%.

News

SILJ, HACK, THNR: Trends in Thematic Investing

Amplify Junior Silver Miners ETF (SILJ) is up 28% year-to-date. Christian Magoon discusses the outlook for cybersecurity stocks, as Amplify's Cybersecurity ETF (HACK) is up 8% year-to-date.

Other symbols: HACKSILJ
1 year ago - Schwab Network

Why Investors Haven't Feasted on Two New Weight-Loss ETFs

Two new weight-loss exchange-traded funds (ETFs) launched in May have yet to whet investors' appetite, possibly due to their expensive fees and concentrated bets.

Other symbols: OZEM
1 year ago - Investopedia